Fig. 7: Clinical significance of miR-30d/RUNX1/SLC2A1/HK1 axis in PDAC patients.

a Representative immunohistochemical images (left) of RUNX1, HK1 and SLC2A1 in PDAC tissues and adjacent nontumor tissues using IHC analysis and statistical analysis of proportion of high, moderate, and low staining in PDAC and paired adjacent tissues (right) in the Shanghai cohort. Scale Bars, up: 200 μm; down: 50 μm. b Expression analysis of RUNX1/HK1/SLC2A1 in PDAC and matching normal pancreatic tissue samples in the GSE102238 dataset. c Representative in situ hybridization images of miR-30d and immunohistochemical images of RUNX1 expression in PDAC with miR-30d low expression and high expression (left), and statistical analysis of PDAC tissues under different staining conditions (right). Scale Bars, up: 200 μm; down: 50 μm. d Representative immunohistochemical images of RUNX1 and HK1/SLC2A1 expression in PDAC with RUNX1 low expression and high expression (left), and statistical analysis of PDAC tissues under different staining conditions (right). Scale Bars, up: 200 μm; down: 50 μm. e Correlation between RUNX1 expression and HK1/SLC2A1 expression of pancreatic tissues in 2 GEO datasets (GSE62452, GSE62165). The square in the upper right corner demonstrates the Pearson correlation value between the indicated genes with blue indicating negative correlation and red indicating positive correlation. The square in the lower left corner shows the scatterplot matrix fitted trend line for indicated genes. **, correlation is significant at the 0.01 level. f Kaplan–Meier analysis of overall survival between PDAC patients with miR-30d low expression and three highly expressed markers RUNX1/SLC2A1/HK1 and those with miR-30d high expression and three lowly expressed markers RUNX1/SLC2A1/HK1 in the PDAC TMA. g Schematic diagram of the relationship among YTHDC1, miR-30d, RUNX1, HK1, SLC2A1, glycolysis metabolism, and pancreatic tumorigenesis.